title: Bone remodelling is reduced by recovery from iron-deficiency anaemia in premenopausal women.
abstract: Iron-deficiency anaemia (IDA), one of the most common and widespread health disorders worldwide, affects fundamental metabolic functions and has been associated with deleterious effects on bone. Our aim was to know whether there are differences in bone remodelling between a group of premenopausal IDA women and a healthy group, and whether recovery of iron status has an effect on bone turnover markers. Thirty-five IDA women and 38 healthy women (control group) were recruited throughout the year. IDA women received pharmacological iron treatment. Iron biomarkers, aminoterminal telopeptide of collagen I (NTx), procollagen type 1 N-terminal propeptide (P1NP), 25-hydroxyvitamin D, and parathormone (PTH) were determined at baseline for both groups and after treatment with pharmacological iron for the IDA group. IDA subjects were classified as recovered (R) or non-recovered (nR) from IDA after treatment. NTx levels were significantly higher (p <0.001), and P1NP levels tended to be lower in IDA women than controls after adjusting for age and body mass index (BMI), with no differences in 25-hydroxyvitamin D or PTH. After treatment, the R group had significantly lower NTx and P1NP levels compared to baseline (p <0.05 and p <0.001 respectively), whilst no significant changes were seen in the nR group. No changes were seen in 25-hydroxyvitamin D or PTH for either group. IDA is related to higher bone resorption independent of age and BMI. Recovery from IDA has a concomitant beneficial effect on bone remodelling in premenopausal women, decreasing both bone resorption and formation.
authors.affiliation: Institute of Food Science, Technology and Nutrition (ICTAN), Spanish National Research Council (CISC), C/José Antonio Novais 10, 28040, Madrid, Spain.
authors.forename: Ione
authors.initials: I
authors.lastname: Wright
authors.forename: Ruth
authors.initials: R
authors.lastname: Blanco-Rojo
authors.forename: M Cristina
authors.initials: MC
authors.lastname: Fernández
authors.forename: Laura
authors.initials: L
authors.lastname: Toxqui
authors.forename: Gemma
authors.initials: G
authors.lastname: Moreno
authors.forename: Ana M
authors.initials: AM
authors.lastname: Pérez-Granados
authors.forename: Concepción
authors.initials: C
authors.lastname: de la Piedra
authors.forename: Ángel F
authors.initials: ÁF
authors.lastname: Remacha
authors.forename: M Pilar
authors.initials: MP
authors.lastname: Vaquero
mesh_terms: D000293:Adolescent; D000328:Adult; D018798:Anemia, Iron-Deficiency / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000652:urine; D015415:Biomarkers / Q000097:blood / Q000652:urine; D001862:Bone Resorption / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000652:urine; D016022:Case-Control Studies; D024042:Collagen Type I / Q000652:urine; D005260:Female; D005296:Ferrous Compounds / Q000627:therapeutic use*; D006397:Hematinics / Q000627:therapeutic use*; D006801:Humans; D007501:Iron / Q000378:metabolism*; D010281:Parathyroid Hormone / Q000097:blood; D010446:Peptide Fragments / Q000097:blood; D010455:Peptides / Q000652:urine; D017697:Premenopause; D011347:Procollagen / Q000097:blood; D014807:Vitamin D / Q000031:analogs & derivatives / Q000097:blood
chemical_list: D015415:Biomarkers; D024042:Collagen Type I; D005296:Ferrous Compounds; D006397:Hematinics; D010281:Parathyroid Hormone; D010446:Peptide Fragments; D010455:Peptides; D011347:Procollagen; C052929:collagen type I trimeric cross-linked peptide; C047202:procollagen Type I N-terminal peptide; D014807:Vitamin D; C020748:ferrous sulfate; C104450:25-hydroxyvitamin D; D007501:Iron